Indeed, ADT is generally administered to PC patients on a lifelong basis in combination with Docetaxel (or its second-generation derivative Cabazitaxel) [9], drugs as androgen pathway inhibitors [10], or poly(ADP-ribose) polymerase inhibitors (PARPi) [11], considering the role of the androgen receptor (AR) for the tumor proliferation in mCRPC [12]. Here, AR is linked to neoplasm.